Pharmacokinetics of oral and intravenous melatonin in healthy volunteers

Lars P H Andersen, Mads U Werner, Mette M Rosenkilde, Nathja G Harpsøe, Hanne Fuglsang, Jacob Rosenberg, Ismail Gögenur, Lars P H Andersen, Mads U Werner, Mette M Rosenkilde, Nathja G Harpsøe, Hanne Fuglsang, Jacob Rosenberg, Ismail Gögenur

Abstract

Background: The aim was to investigate the pharmacokinetics of oral and iv melatonin in healthy volunteers.

Methods: The study was performed as a cohort crossover study. The volunteers received either 10 mg oral melatonin or 10 mg intravenous melatonin on two separate study days. Blood samples were collected at different time points following oral administration and short iv infusion, respectively. Plasma melatonin concentrations were determined by RIA technique. Pharmacokinetic analyses were performed by "the method of residuals" and compartmental analysis. The pharmacokinetic variables: k a, t 1/2 absorption, t max, C max, t 1/2 elimination, AUC 0-∞, and bioavailability were determined for oral melatonin. C max, t 1/2 elimination, V d, CL and AUC 0-∞ were determined for intravenous melatonin.

Results: Twelve male volunteers completed the study. Baseline melatonin plasma levels did not differ significantly between the study days (P = 0.067). Mean (SD) t 1/2 absorption of oral melatonin was 6.0 (3.1) min. Mean t max was 40.8 (17.8) min with a median (IQR) C max of 3550.5 (2500.5-8057.5) pg ml(-1). Mean t 1/2 elimination was 53.7 (7.0) min. Median absolute bioavailability was 2.5 (1.7-4.7) %. Median C max after short iv infusion of melatonin was 389,875.0 (174,775.0-440,362.5) pg ml(-1). Mean t 1/2 elimination was 39.4 (3.6) min, mean V d 1.2 (0.6) l kg(-1) and mean CL 0.0218 (0.0102) l min(-1) kg(-1).

Conclusions: This cohort crossover study estimated pharmacokinetics of oral and iv melatonin, respectively in healthy volunteers. Bioavailability of oral melatonin was only 3 %.

Trial registration: Eudra-CT number: 2013-000205-23 (initial registration 27.03.2013). Clinicaltrials.gov Identifier: NCT01923974 (initial registration 08.08.2013).

Figures

Fig. 1
Fig. 1
Pharmacokinetic profile of 10 mg of oral melatonin. The dots represent mean values. Whiskers represent SEM
Fig. 2
Fig. 2
Individual pharmacokinetic profiles of 10 mg of iv melatonin

References

    1. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336:186–95. doi: 10.1056/NEJM199701163360306.
    1. Andersen LP, Werner MU, Rosenberg J, Gögenur I. A systematic review of peri-operative melatonin. Anaesthesia. 2014;69:1163–71. doi: 10.1111/anae.12717.
    1. Gögenur I, Kücükakin B, Panduro Jensen L, Reiter RJ, Rosenberg J. Melatonin reduces cardiac morbidity and markers of myocardial ischemia after elective abdominal aortic aneurism repair: a randomized, placebo-controlled, clinical trial. J Pineal Res. 2014;57:10–5. doi: 10.1111/jpi.12138.
    1. Harpsøe NG, Andersen LP, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol. 2015;71:901–9. doi: 10.1007/s00228-015-1873-4.
    1. Di WL, Kadva A, Johnston A, Silman R. Variable bioavailability of oral melatonin. N Engl J Med. 1997;336:1028–9. doi: 10.1056/NEJM199704033361418.
    1. DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS., Jr The absolute bioavailability of oral melatonin. J Clin Pharmacol. 2000;40:781–4. doi: 10.1177/00912700022009422.
    1. American Society of Anesthesiologists Committee Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters. Anesthesiology. 2011;114:495–511. doi: 10.1097/ALN.0b013e3181fcbfd9.
    1. Waldhauser F, Waldhauser M, Lieberman HR, Deng MH, Lynch HJ, Wurtman RJ. Bioavailability of oral melatonin in humans. Neuroendocrinology. 1984;39:307–13. doi: 10.1159/000123997.
    1. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990;300:230–5. doi: 10.1136/bmj.300.6719.230.
    1. Cavallo A, Ritschel WA. Pharmacokinetics of melatonin in human sexual maturation. J Clin Endocrinol Metab. 1996;81:1882–6.
    1. Markantonis SL, Tsakalozou E, Paraskeva A, Staikou C, Fassoulaki A. Melatonin pharmacokinetics in premenopausal and postmenopausal healthy female volunteers. J Clin Pharmacol. 2008;48:240–5. doi: 10.1177/0091270007311112.
    1. Fourtillan JB, Brisson AM, Gobin P, Ingrand I, Decourt JP, Girault J. Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. Biopharm Drug Dispos. 2000;21:15–22. doi: 10.1002/1099-081X(200001)21:1<15::AID-BDD215>;2-H.
    1. Mallo C, Zaĭdan R, Galy G, Vermeulen E, Brun J, Chazot G, et al. Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur J Clin Pharmacol. 1990;38:297–301. doi: 10.1007/BF00315035.
    1. Härtter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol. 2003;56:679–82. doi: 10.1046/j.1365-2125.2003.01933.x.
    1. Ursing C, von Bahr C, Brismar K, Röjdmark S. Influence of cigarette smoking on melatonin levels in man. Eur J Clin Pharmacol. 2005;61:197–201. doi: 10.1007/s00228-005-0908-7.
    1. Hilli J, Korhonen T, Turpeinen M, Hokkanen J, Mattila S, Laine K. The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2g.-163C > A polymorphism. J Clin Pharmacol. 2008;48:986–94. doi: 10.1177/0091270008318669.
    1. Bourne RS, Mills GH, Minelli C. Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial. Crit Care. 2008;12:R52. doi: 10.1186/cc6871.
    1. Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P, et al. Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res. 2010;48:142–7. doi: 10.1111/j.1600-079X.2009.00737.x.
    1. Gooneratne NS, Edwards AY, Zhou C, Cuellar N, Grandner MA, Barrett JS. Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res. 2012;52:437–45. doi: 10.1111/j.1600-079X.2011.00958.x.
    1. Federico S, Carrano R, Capone D, Gentile A, Palmiero G, Basile V. Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation. Clin Pharmacokinet. 2006;45:169–75. doi: 10.2165/00003088-200645020-00003.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren